Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics Inc. reports developments in molecular diagnostic testing and precision medicine, with recurring updates on tests that assess disease risk, disease progression, and treatment selection across medical specialties. Company news commonly covers the Cancer Care Continuum, Prenatal Health, and Mental Health businesses, including test volume trends, average revenue per test, earnings results, and financial guidance.
Updates also address Myriad's oncology diagnostics and research programs, including MyChoice CDx, Precise MRD, Prolaris, hereditary cancer testing, GeneSight, and prenatal testing products. News themes include companion diagnostic approvals, clinical data presentations, commercial launches, collaborations, and investor healthcare conference participation.
Myriad Genetics (NASDAQ: MYGN) reported third quarter 2025 results: revenue $205.7M (down 4% YoY, flat ex‑$8.1M headwinds), gross margin 69.9%, GAAP net loss $27.4M (loss per share $0.29) and adjusted EPS $0.00. Third quarter adjusted EBITDA was $10.3M and test volumes rose to 386,000 (+3% YoY), led by hereditary cancer volume +11%.
The company entered a strategic collaboration with SOPHiA GENETICS for liquid biopsy CDx development, closed a $200M term loan in July, and ended the quarter with $145.4M cash. Myriad reiterated full‑year 2025 guidance: Revenue $818–$828M, gross margin 69.5%–70.0%, adjusted EBITDA $27–$33M, adjusted EPS $(0.02)–$0.02.
Myriad Genetics (NASDAQ: MYGN) reported a post-hoc analysis of the PRIME study showing GeneSight-informed treatment produced faster remission and response in major depressive disorder.
The PRIME trial enrolled 1,944 U.S. Veterans. The analysis, published Oct 30, 2025 in Frontiers in Pharmacology, found GeneSight patients were 27% more likely to achieve remission and 21% more likely to experience response at any time during the 24-week study, with benefits persisting through six months. Myriad plans to submit these data to payers to support access to GeneSight.
Myriad Genetics (NASDAQ: MYGN) will release its third quarter 2025 financial results on November 3, 2025 after market close and will host an earnings conference call the same day at 4:30 PM ET. Management will provide a financial overview and business update for Q3 2025.
A live webcast will be available on Myriad’s Investor Relations website at investor.myriad.com. Telephone participants must register to receive a dial-in number and unique PIN. An archived webcast will be posted at investor.myriad.com following the call.
Myriad Genetics (NASDAQ: MYGN) announced on October 14, 2025 that it added the F8 and FXN genes to the Foresight® Carrier Screen Universal Plus Panel. The company said the additions meet its clinical-selection criteria and that testing is processed in its state-of-the-art facility.
The update makes the Foresight Carrier Screen fully compliant with ACMG recommendations. The release notes F8's link to hemophilia A and FXN's link to Friedreich's ataxia and references the FDA's 2023 approval of omaveloxolone for FA in patients aged 16+.
Myriad Genetics (Nasdaq: MYGN) and SOPHiA GENETICS (Nasdaq: SOPH) have announced a strategic collaboration to develop a global liquid biopsy companion diagnostic (CDx) test. The partnership combines Myriad's U.S. laboratory capabilities with SOPHiA GENETICS' network of over 800 institutions across 70+ countries.
The initial focus will be on MSK-ACCESS® powered with SOPHiA DDM™, a liquid biopsy test developed with Memorial Sloan Kettering Cancer Center that detects genomic alterations from blood samples using ctDNA analysis. Myriad will handle U.S. regulatory submissions, while SOPHiA GENETICS will manage international regulatory processes.
Myriad Genetics (NASDAQ: MYGN) announced the publication of clinical data for its Precise MRD test in The Lancet Oncology. The study focused on patients with oligometastatic clear-cell renal cell carcinoma (ccRCC) and demonstrated significant results in detecting circulating tumor DNA (ctDNA).
The Phase 2 trial revealed that 94% of patients had ctDNA levels below 100 ppm at baseline. Patients testing negative with Precise MRD maintained metastasis-directed therapy for a median of 54 months, compared to 27 months for ctDNA-positive patients. Notably, ctDNA-negative patients showed strong survival rates of 94% at two years and 87% at three years.
Myriad Genetics (NASDAQ: MYGN) announced significant findings from a meta-analysis of six prospective controlled studies involving 3,532 adults with major depressive disorder (MDD). The analysis, published in the Journal of Clinical Psychopharmacology, demonstrated that patients whose clinicians had access to GeneSight® Psychotropic test results showed markedly improved outcomes compared to traditional treatment.
The study revealed that patients in the GeneSight arm were 41% more likely to achieve remission and 30% more likely to achieve response compared to treatment as usual (TAU). The company plans to submit this data to payers to increase patient access to the GeneSight test.
Myriad Genetics (NASDAQ:MYGN), a molecular diagnostic testing and precision medicine company, announced its participation in two upcoming healthcare investor conferences. Management will present at the Wells Fargo Healthcare Conference on September 4, 2025, at 3:45 PM ET and the Morgan Stanley Annual Global Healthcare Conference on September 10, 2025, at 7:45 AM ET. Both presentations will be available via webcast on the company's investor relations website.
ANGLE plc (OTCQX:ANPCY) has announced a strategic collaboration with Myriad Genetics (NASDAQ:MYGN) to evaluate the feasibility of using Parsortix-derived circulating tumor cell (CTC) DNA with Myriad's existing tissue-based diagnostic tests.
Under the agreement, ANGLE's R&D team will process cancer patient blood samples using their Parsortix® system to capture intact cancer cells for molecular analysis. The study will compare CTC-DNA results with matched patient tissue samples using Myriad's current tissue-based assay. The specific terms of the agreement remain confidential between the parties.
Myriad Genetics (NASDAQ: MYGN) has announced the promotion of Ben Wheeler to Chief Financial Officer, effective August 16, 2025. Wheeler, a 13-year company veteran, previously served as chief financial officer of operations and has held various leadership roles since joining in 2011.
The appointment follows Scott Leffler's transition to a consulting role through September 2, 2025. CEO Sam Raha expressed confidence in Wheeler's ability to execute the company's profitable growth strategy. The company has also reaffirmed its full-year 2025 financial guidance as previously announced on August 5, 2025.